Cargando…

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins

Accurate orchestration of gene expression is critical for the process of normal hematopoiesis, and dysregulation is closely associated with leukemogenesis. Epigenetic aberration is one of the major causes contributing to acute myeloid leukemia (AML), where chromosomal rearrangements are frequently f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Juan, Gao, Xuefeng, Yu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440836/ https://www.ncbi.nlm.nih.gov/pubmed/34540702 http://dx.doi.org/10.3389/fonc.2021.741746

Ejemplares similares

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Characteristics of Cohesin Mutation in Acute Myeloid Leukemia and Its Clinical Significance
por: Han, Caixia, et al.
Publicado: (2021)

Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
por: Dhall, Abhinav, et al.
Publicado: (2019)

The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells
por: Ma, Xiangyu, et al.
Publicado: (2022)

Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges
por: Kang, Synat, et al.
Publicado: (2022)

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia
por: Min, Chengyin, et al.
Publicado: (2017)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

Case report: A rare case of acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia
por: Zhao, Junmei, et al.
Publicado: (2022)

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors
por: Khateb, Ali, et al.
Publicado: (2021)

Characterization of Histone Deacetylase Mechanisms in Cancer Development
por: Hai, Rihan, et al.
Publicado: (2021)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
por: Guo, Fengyi, et al.
Publicado: (2022)

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
por: Ungerstedt, Johanna S.
Publicado: (2018)

Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia
por: Pfeiffer, Matthias Manuel, et al.
Publicado: (2013)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
por: Dembitz, Vilma, et al.
Publicado: (2021)

The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia
por: Ng, Michelle, et al.
Publicado: (2019)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
por: Xu, Xuelian, et al.
Publicado: (2011)

Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine
por: Sterner, Rosalie M., et al.
Publicado: (2017)

Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
por: Feng, Lili, et al.
Publicado: (2023)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
por: Shojaei, Farbod, et al.
Publicado: (2022)

Murine Models of Acute Myeloid Leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2022)

Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy
por: Johnson, Alicia M., et al.
Publicado: (2021)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
por: Barbosa, Karina, et al.
Publicado: (2023)

High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
por: Zhao, Wenxiu, et al.
Publicado: (2022)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

Clinical Implications of Inflammation in Acute Myeloid Leukemia
por: Récher, Christian
Publicado: (2021)

Genomics of Acute Myeloid Leukemia: The Next Generation
por: Riva, Laura, et al.
Publicado: (2012)

Editorial: Precision medicine for acute myeloid leukemia
por: Marconi, Giovanni, et al.
Publicado: (2023)

Corrigendum: Murine models of acute myeloid leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2023)

Research progress on molecular biomarkers of acute myeloid leukemia
por: Yin, Pei-Yuan, et al.
Publicado: (2023)

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
por: Arriazu, Elena, et al.
Publicado: (2016)

Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia
por: Ramaswamy, Kavitha, et al.
Publicado: (2015)

THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia
por: Zhu, Lidan, et al.
Publicado: (2020)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions
por: Su, Long, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qgu4t9i1lr8btlr7eskeisbknv